SI2243829T1 - Izboljšano humanizirano anti-humano alfa9-integrinsko protitelo - Google Patents

Izboljšano humanizirano anti-humano alfa9-integrinsko protitelo

Info

Publication number
SI2243829T1
SI2243829T1 SI200931034T SI200931034T SI2243829T1 SI 2243829 T1 SI2243829 T1 SI 2243829T1 SI 200931034 T SI200931034 T SI 200931034T SI 200931034 T SI200931034 T SI 200931034T SI 2243829 T1 SI2243829 T1 SI 2243829T1
Authority
SI
Slovenia
Prior art keywords
humanized anti
integrin antibody
improved humanized
human alpha9
alpha9
Prior art date
Application number
SI200931034T
Other languages
English (en)
Inventor
Kenji Uehara
Hirofumi Higuchi
Toshihiro Nakashima
Daisuke Ishikawa
Nobuchika Yamamoto
Hirotada Fujita
Fumihiko Sakai
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of SI2243829T1 publication Critical patent/SI2243829T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SI200931034T 2008-01-11 2009-01-09 Izboljšano humanizirano anti-humano alfa9-integrinsko protitelo SI2243829T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2008004975 2008-01-11
JP2008282496 2008-10-31
PCT/JP2009/050187 WO2009088064A1 (ja) 2008-01-11 2009-01-09 改良型ヒト化抗ヒトα９インテグリン抗体
EP09700904.7A EP2243829B1 (en) 2008-01-11 2009-01-09 IMPROVED HUMANIZED ANTI-HUMAN alpha9-INTEGRIN ANTIBODY

Publications (1)

Publication Number Publication Date
SI2243829T1 true SI2243829T1 (sl) 2014-11-28

Family

ID=40853174

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200931034T SI2243829T1 (sl) 2008-01-11 2009-01-09 Izboljšano humanizirano anti-humano alfa9-integrinsko protitelo

Country Status (21)

Country Link
US (2) US8603476B2 (sl)
EP (2) EP2243829B1 (sl)
JP (2) JP5440179B2 (sl)
KR (1) KR101634636B1 (sl)
CN (1) CN101918549B (sl)
AU (1) AU2009203369B2 (sl)
BR (1) BRPI0905656B8 (sl)
CA (1) CA2711882C (sl)
CY (1) CY1115897T1 (sl)
DK (1) DK2243829T3 (sl)
ES (1) ES2519047T3 (sl)
HR (1) HRP20141110T1 (sl)
IL (1) IL206898A (sl)
MX (1) MX2010007515A (sl)
PL (1) PL2243829T3 (sl)
PT (1) PT2243829E (sl)
RU (1) RU2503720C2 (sl)
SI (1) SI2243829T1 (sl)
TW (1) TWI432453B (sl)
WO (2) WO2009088064A1 (sl)
ZA (1) ZA201004770B (sl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2406285B1 (en) * 2009-03-10 2016-03-09 Gene Techno Science Co., Ltd. Generation, expression and characterization of the humanized k33n monoclonal antibody
WO2011004847A1 (ja) * 2009-07-07 2011-01-13 一般財団法人化学及血清療法研究所 新規ヒト化抗ヒトα９インテグリン抗体
KR101783929B1 (ko) * 2011-05-06 2017-10-11 넥스베트 오스트레일리아 피티와이 리미티드 항신경성 성장 인자 항체 및 그의 제조방법과 이용방법
CA2851758A1 (en) * 2011-10-13 2013-04-18 Nvip Pty Ltd Canine/feline cd20 binding epitope and compositions for binding thereto
JP2021008406A (ja) * 2017-09-29 2021-01-28 アステラス製薬株式会社 改良型ヒト化抗ヒトα９インテグリン抗体含有医薬組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JP3855071B2 (ja) 1993-03-11 2006-12-06 財団法人化学及血清療法研究所 抗ｈｉｖモノクローナル抗体
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6939855B2 (en) * 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
CA2443330A1 (en) 2001-04-05 2002-10-17 Toshimitsu Uede Anti-osteopontin antibody and use thereof
CA2461529A1 (en) * 2001-09-25 2003-04-03 Immuno-Biological Laboratories Co., Ltd. Recombinant anti-osteopontin antibody and use thereof
AU2003256307A1 (en) * 2002-06-25 2004-01-06 The Regents Of The University Of California Methods for inhibiting angiogenesis, cell migration, cell adhesion, and cell survival
EP2990422B1 (en) 2004-09-03 2018-07-11 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
KR101316990B1 (ko) * 2005-01-13 2013-10-11 가부시키가이샤 진 테크노 사이언스 항-α9 인테그린 항체와 그 용도
CA2653661A1 (en) 2006-05-31 2007-12-06 Astellas Pharma Inc. Humanized anti-human osteopontin antibody
JP4841326B2 (ja) 2006-06-20 2011-12-21 三菱電機株式会社 ホームネットワークシステム
KR101429783B1 (ko) * 2006-07-12 2014-08-18 가부시키가이샤 진 테크노 사이언스 항 인간 α９ 인테그린 항체와 그 용도
JP2008282496A (ja) 2007-05-11 2008-11-20 Konica Minolta Opto Inc 光ピックアップ装置
JP2007302676A (ja) * 2007-05-29 2007-11-22 Genentech Inc ヒト化抗β７アンタゴニストおよびその使用

Also Published As

Publication number Publication date
PL2243829T3 (pl) 2015-04-30
EP2243829B1 (en) 2014-08-20
CA2711882C (en) 2016-07-19
TWI432453B (zh) 2014-04-01
HRP20141110T1 (hr) 2015-01-16
ZA201004770B (en) 2011-03-30
EP2243829A4 (en) 2012-05-23
US8603476B2 (en) 2013-12-10
DK2243829T3 (da) 2014-11-17
BRPI0905656A8 (pt) 2017-05-09
CN101918549A (zh) 2010-12-15
CA2711882A1 (en) 2009-07-16
JPWO2009088065A1 (ja) 2011-05-26
PT2243829E (pt) 2014-10-24
KR20100110852A (ko) 2010-10-13
JPWO2009088064A1 (ja) 2011-05-26
EP2243829A1 (en) 2010-10-27
JP5440179B2 (ja) 2014-03-12
AU2009203369A1 (en) 2009-07-16
US20110059077A1 (en) 2011-03-10
BRPI0905656B8 (pt) 2021-05-25
BRPI0905656A2 (pt) 2015-07-07
IL206898A (en) 2015-06-30
IL206898A0 (en) 2010-12-30
EP2239323A1 (en) 2010-10-13
BRPI0905656B1 (pt) 2020-03-31
RU2010133550A (ru) 2012-02-20
CN101918549B (zh) 2012-11-28
MX2010007515A (es) 2010-11-12
WO2009088065A1 (ja) 2009-07-16
EP2239323A4 (en) 2012-05-23
TW200932759A (en) 2009-08-01
KR101634636B1 (ko) 2016-06-29
ES2519047T3 (es) 2014-11-06
CY1115897T1 (el) 2017-01-25
AU2009203369B2 (en) 2014-04-03
US20110014193A1 (en) 2011-01-20
WO2009088064A1 (ja) 2009-07-16
RU2503720C2 (ru) 2014-01-10

Similar Documents

Publication Publication Date Title
ZA201005348B (en) Humanized anti-c5ar antibodies
IL239947A0 (en) Monoclonal antibodies against 21-il of human origin
EP2349331A4 (en) HUMANIZED ANTIBODIES TO IL-6
IL204835A0 (en) Humanized antibody
EP2331579A4 (en) MONOCLONAL ANTIBODIES
ZA201004752B (en) Humanized anti-human nkg2a monoclonal antibody
SG10201601279SA (en) Monoclonal Antibody STRO-4
ZA201008993B (en) Anti-human interleukin-20 antibodies
IL217919A0 (en) Humanized anti-cdcp1 antibodies
PL2262831T4 (pl) Przeciwciała przeciwko properdynie
HK1168871A1 (zh) 單克隆抗體
HK1184470A1 (zh) 抗人 抗體
IL199974A0 (en) Humanized antibodies against cxcr3
ZA201004770B (en) Improved humanized anti-human x9-integrin antibody
GB0804684D0 (en) Humanized antibody
GB0804686D0 (en) Humanized antibody
GB0804687D0 (en) Humanized antibody
TWI348915B (en) Anti-vegf monoclonal antibody
GB0706963D0 (en) Humanized antibody
GB0706965D0 (en) Humanized antibody
GB0706964D0 (en) Humanized antibody